Seqirus
seqirus.comTotal trials
53
Active
1
Phase 3
20
Total enrollment
117,179
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| aQIV or aTIV | — | — | — | — | — | 1 | |
| QIV or TIV | — | — | — | — | — | 1 |
Next readouts
- 2026-11
Top conditions
- Influenza26
- Influenza, Human23
- Virus Diseases4
- Infections3
- Respiratory Tract Infections3
- Human2
- Pregnancy2
- Birth Defect2
Frequently asked questions about Seqirus
- How many clinical trials does Seqirus have on ClinicalTrials.gov?
- Seqirus is listed as the lead sponsor on 53 clinical trials in ClinicalTrials.gov, 1 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Seqirus's trials are in Phase 3?
- 20 of Seqirus's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Seqirus focus on?
- Seqirus's most-studied conditions on ClinicalTrials.gov are Influenza, Influenza, Human, Virus Diseases, Infections, Respiratory Tract Infections.
- When are Seqirus's next clinical trial readouts?
- Seqirus has 1 upcoming primary-completion readout tracked here; the soonest is “A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age”, expected around 2026-11.